目前，省略腋窝分期的唯一机会是针对年龄 > 70 岁的 cT1 2N0 雌激素受体阳性/人表皮生长因子受体 2 阴性乳腺癌女性的“明智选择”标准。然而，许多女性在病理淋巴结状态阴性时被诊断出来，这就提出了是否有更多机会省略前哨淋巴结活检的问题。我们试图调查 MammaPrint（一种估计雌激素受体阳性乳腺癌复发风险的基因组测试）与病理淋巴结状态之间的关联，目的是如果与病理淋巴结状态相关，则可以考虑低风险 MammaPrint 来省略前哨淋巴结活检。节点状态阴性。对单机构数据库进行了查询，查找 2020 年至 2021 年期间所有患有 cT1 2N0 雌激素受体阳性/人表皮生长因子受体 2 阴性浸润性乳腺癌且首次接受乳房手术并进行 MammaPrint 的女性。将包括 MammaPrint 评分在内的肿瘤因素与腋窝淋巴结状态进行比较。共有 668 名女性符合纳入标准，中位年龄为 66 岁。 MammaPrint 在 481 例 (72%) 中为低风险管腔 A，在 187 例 (28%) 中为高风险管腔 B。在乳房手术时，588 例（88%）进行了前哨淋巴结活检，27 例（4%）进行了腋窝淋巴结清扫，53 例（7.9%）没有进行腋窝分期。病理淋巴结状态阴性和病理淋巴结状态阳性队列中的大多数女性的 MammaPrint 风险较低（355 [73.3%] 病理淋巴结状态阴性 vs 91 [69.5%] 病理淋巴结状态阳性）， -risk MammaPrint 并未显着降低病理淋巴结状态阳性的风险 (P = .377)。低风险 MammaPrint 不能预测病理淋巴结状态阳性乳腺癌的风险较低。根据我们的结果，基因组测试似乎并没有为在明智选择指南之外的患者省略前哨淋巴结活检的能力提供额外的个性化服务。版权所有 © 2023 Elsevier Inc. 保留所有权利。

At present, the only opportunity to omit axillary staging is with Choosing Wisely criteria for women ages >70 y with cT1 2N0 estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. However, many women are diagnosed when pathologic node status-negative, raising the question of additional opportunities to omit sentinel lymph node biopsy. We sought to investigate the association between MammaPrint, a genomic test that estimates estrogen receptor-positive breast cancer recurrence risk, and pathologic node status, with the aim that low-risk MammaPrint could be considered for omission of sentinel lymph node biopsy if associated with pathologic node status-negative.A single-institution database was queried for all women with cT1 2N0 estrogen receptor-positive/human epidermal growth factor receptor 2-negative invasive breast cancer with breast surgery as their first treatment and MammaPrint performed from 2020 to 2021. Patient and tumor factors, including MammaPrint score, were compared with axillary node status for correlation.A total of 668 women met inclusion criteria, with a median age of 66 y. MammaPrint was low-risk luminal A in 481 (72%) and high-risk luminal B in 187 (28%). At the time of breast surgery, 588 (88%) had sentinel lymph node biopsy, 27 (4%) had axillary lymph node dissection, and 53 (7.9%) had no axillary staging. Most women in both the pathologic node status-negative and pathologic node status-positive cohorts had low-risk MammaPrint (355 [73.3%] pathologic node status-negative vs 91 [69.5%] pathologic node status-positive), and women with low-risk MammaPrint did not have a significantly lower risk of pathologic node status-positive (P = .377).Low-risk MammaPrint does not predict lower risk of pathologic node status-positive breast cancer. Based on our results, genomic testing does not appear to provide additional personalization for the ability to omit sentinel lymph node biopsy for patients outside of the Choosing Wisely guidelines.Copyright © 2023 Elsevier Inc. All rights reserved.